HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

72.300

+0.3500.49%

Volume:1.44M

Turnover:103.17M

Market Cap:14.39B

PE:-51.21

High:73.850

Open:73.850

Low:69.750

Close:71.950

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.97

T/O Rate:0.73%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.412

ROE:-27.61%

ROA:-9.92%

PB:9.74

PE(LYR):-51.21

PS:69.57

Loading ...

Overview Company News Filings

LEADS BIOLABS-B Nominates Wu Fenglan for Non-Executive Director Role

Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan

Leads Biolabs 2025 Results: Revenue Reaches RMB177.26 Million on Up-Front Licensing; Net Loss Narrows 29.8% to RMB211.42 Million

Bulletin Express

Nanjing Leads Biolabs Co Ltd - FY Revenue RMB177.3 Million

THOMSON REUTERS

Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million

Leads Biolabs-B (09887) Schedules 27 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Dividend

Bulletin Express

Nanjing Leads Biolabs to hold board meeting on annual results and dividend proposal

Leads Biolabs doses first ESCC patient in Phase II Opamtistomig trial

Nanjing Leads Biolabs Joins Hang Seng Composite Index, Stock Connect List

MT Newswires Live

LEADS BIOLABS-B Surges Over 8% in Early Trading, Officially Added to Southbound Trading List

LEADS BIOLABS-B Surges Over 8% on Inclusion in Stock Connect and Clinical Trial Milestone

LEADS BIOLABS-B to Join Hang Seng Composite Index and Become Eligible for Southbound Trading

LEADS BIOLABS-B (09887) Announces Inclusion in Hang Seng Composite Index and Southbound Trading Link

Bulletin Express

LEADS BIOLABS-B (09887) Included in Hang Seng Composite Index and Added to Stock Connect List

Nanjing Leads Biolabs Joins Hang Seng Composite IndexNanjing Leads Biolabs Co., Ltd. said its shares will be added to the Hang Seng Composite Index effective March 9, 2026, and will also be included in the Stock Connect Southbound Trading Link eligible list

LEADS BIOLABS-B (Stock Code: 09887) Announces First Patient Enrolled in Phase II Trial for Opamtistomig in First-Line Esophageal Squamous Cell Carcinoma

Bulletin Express

LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial for VELISIN™ in First-Line Esophageal Squamous Cell Carcinoma

Nanjing Leads Biolabs Enrolls First Patient in Phase II ESCC Trial of LBL-024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/09887/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":72.3,"timestamp":1788163728010,"preClose":71.95,"halted":0,"volume":1444087,"delay":0,"changeRate":0.004864489228630914,"floatShares":198000000,"shares":199000000,"eps":-1.411818424105603,"marketStatus":"Not Yet Opened","change":0.35,"latestTime":"08-31 16:08:48","open":73.85,"high":73.85,"low":69.75,"amount":103174580,"amplitude":0.056984,"askPrice":72.3,"askSize":36900,"bidPrice":72.25,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.3733142852663596,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":71.95,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.9741671036683299,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.411818,"volumeRatio":0.9741671036683299,"shares":199000000,"dividePrice":0,"high":73.85,"amplitude":0.056984,"preClose":71.95,"low":69.75,"week52Low":44.72,"pbRate":"9.74","psRate":"69.57","week52High":97.5,"institutionHeld":0,"latestPrice":72.3,"committee":-0.989218,"eps":-1.411818424105603,"divideRate":0,"volume":1444087,"delay":0,"ttmEps":-1.3733142852663596,"open":73.85,"prevYearClose":51,"prevWeekClose":71.95,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":69.05,"twentyDayClose":56.95,"sixtyDayClose":56.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780243200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-08-28","current":-52.646479,"percent":0.130597,"low":-76.458084,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"high":-30.202688,"avg":-42.108117,"sd":9.834997,"marketCap":14310265010},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010}],"updateTime":1788205359843},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1116228132","title":"LEADS BIOLABS-B Nominates Wu Fenglan for Non-Executive Director Role","url":"https://stock-news.laohu8.com/highlight/detail?id=1116228132","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116228132?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609235,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that Dr. Ni Jia has tendered her resignation as a non-executive director of the company, effective March 27, 2026. Following the recommendation of the board's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","09887","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622284948","title":"Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2622284948","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622284948?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:54","pubTimestamp":1774608885,"startTime":"0","endTime":"0","summary":"Non-executive director Ni Jia resigned, effective March 27, 2026.The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.Wu previously served as a scientist at GlaxoSmithKline, and later held roles at Zai Lab, China Renaissance, and Gritgen Therapeutics.She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2Y01zT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481600234.SGD","LU0321505439.SGD","LU1481599808.USD","LU1228905037.USD","IE0034235071.USD","LU1400636657.SGD","LU0306807586.USD","SG9999001176.USD","BK1161","BK1574","LU1983299246.USD","SG9999013999.USD","LU0058720904.USD","LU0225771236.USD","LU1645745479.HKD","LU0985481810.HKD","SG9999001176.SGD","IE00BWDBJ516.SGD","LU0971552830.HKD","LU1046248800.SGD","LU1202635105.USD","LU1035777561.USD","LU1309081286.SGD","SGXZ57979304.SGD","GSK.UK","LU1400636491.USD","LU0971552673.USD","HK0000252160.HKD","09688","LU0109981661.USD","LU0203345920.USD","LU1015430645.USD","09887","LU0211331839.USD","LU0289739699.SGD","HK0000500386.USD","LU0161305163.EUR","LU1228905540.USD","LU0321505868.SGD","LU1670756490.USD","LU1064927863.SGD","LU2488822045.USD","IE00B3T34201.USD","LU0306806265.USD","BK1588","LU0545562505.USD","LU0225284248.USD","LU0575583348.USD","LU1302929846.USD","IE00BQJZX424.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124822191","title":"LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124822191","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124822191?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:11","pubTimestamp":1774602704,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","BK1161","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181768552","title":"Leads Biolabs 2025 Results: Revenue Reaches RMB177.26 Million on Up-Front Licensing; Net Loss Narrows 29.8% to RMB211.42 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1181768552","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181768552?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:04","pubTimestamp":1774602242,"startTime":"0","endTime":"0","summary":"Leads Biolabs (Nanjing Leads Biolabs Co., Ltd.) released its audited 2025 annual results. Financial Highlights   • Revenue: RMB177.26 million, versus zero in 2024, driven entirely by upfront and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622841100","title":"Nanjing Leads Biolabs Co Ltd - FY Revenue RMB177.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841100?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:02","pubTimestamp":1774602122,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F04E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622841469","title":"Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841469?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:01","pubTimestamp":1774602109,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.Loss for the year narrowed 29.8% to RMB211.4 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8jwpM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158227991","title":"Leads Biolabs-B (09887) Schedules 27 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1158227991","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158227991?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:43","pubTimestamp":1773737026,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (stock name: Leads Biolabs-B; stock code: 09887) has announced that its board of directors will convene on Friday, 27 March 2026. The agenda includes: 1. Approval and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620442566","title":"Nanjing Leads Biolabs to hold board meeting on annual results and dividend proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442566?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:31","pubTimestamp":1773736295,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs will hold a board meeting on 27 March 2026 to consider and approve its annual results for the year ended 31 December 2025. The board will also consider a dividend recommendation at the same meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL5hBv4Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617560","title":"Leads Biolabs doses first ESCC patient in Phase II Opamtistomig trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617560","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617560?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:28","pubTimestamp":1773037739,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. reported that the first patient has been dosed in an open-label, multi-center Phase II clinical study of opamtistomig , a PD-L1/4-1BB bispecific antibody, as first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma in China. The study is led by Professor Shen Lin of Beijing Cancer Hospital and will assess the drug’s efficacy and safety across multiple hospitals. No trial results were presented in the announcement; results are expected to be reported in the future.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL9DLhvK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618261504","title":"Nanjing Leads Biolabs Joins Hang Seng Composite Index, Stock Connect List","url":"https://stock-news.laohu8.com/highlight/detail?id=2618261504","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618261504?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:09","pubTimestamp":1773025761,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  said its shares will be included as a constituent of the Hang Seng Composite Index and added to the Stock Connect Southbound Trading Link, according to a March 6 Hong Kong bourse filing.Shares of the clinical-stage biotech company gained nearly 5% in Monday morning trade.The inclusion will take effect March 9, allowing eligible mainland investors to trade the company's Hong Kong-listed shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","HSCI","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189430822","title":"LEADS BIOLABS-B Surges Over 8% in Early Trading, Officially Added to Southbound Trading List","url":"https://stock-news.laohu8.com/highlight/detail?id=1189430822","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189430822?lang=en_us&edition=fundamental","pubTime":"2026-03-09 10:44","pubTimestamp":1773024294,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw an increase of more than 8% at the start of trading. At the time of writing, the stock was up 6.04%, trading at HK$57.10, with a turnover of HK$115 million. The company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","BK4588","09887","VT","VXUS","BK4585","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195884849","title":"LEADS BIOLABS-B Surges Over 8% on Inclusion in Stock Connect and Clinical Trial Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1195884849","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195884849?lang=en_us&edition=fundamental","pubTime":"2026-03-09 10:34","pubTimestamp":1773023659,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 8%. At the time of writing, the stock was up 8.08% to HK$58.05, with a turnover of HK$110 million. On the news front, LEADS BIOLABS announced that, effective...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","HK0000252160.HKD","09887","BK4588","VT","BK1161","HK0000500386.USD","BK4585","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199922475","title":"LEADS BIOLABS-B to Join Hang Seng Composite Index and Become Eligible for Southbound Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199922475","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199922475?lang=en_us&edition=fundamental","pubTime":"2026-03-08 10:20","pubTimestamp":1772936446,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that, effective March 9, 2026, the company's shares will be included as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited and will...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VT","HK0000252160.HKD","VXUS","BK1161","HSCI","HK0000500386.USD","BK4588","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136889806","title":"LEADS BIOLABS-B (09887) Announces Inclusion in Hang Seng Composite Index and Southbound Trading Link","url":"https://stock-news.laohu8.com/highlight/detail?id=1136889806","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136889806?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:23","pubTimestamp":1772789002,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (LEADS BIOLABS-B) (Stock Code: 09887) announced that, effective March 9, 2026, its shares will be included as a constituent stock of the Hang Seng Composite Index by...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188540988","title":"LEADS BIOLABS-B (09887) Included in Hang Seng Composite Index and Added to Stock Connect List","url":"https://stock-news.laohu8.com/highlight/detail?id=1188540988","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188540988?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:18","pubTimestamp":1772788704,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that, effective March 9, 2026, the company's shares will be included as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited and added...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VT","BK4585","09887","BK1161","HK0000500386.USD","HSCI","HK0000252160.HKD","HK0000252152.HKD","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617468687","title":"Nanjing Leads Biolabs Joins Hang Seng Composite IndexNanjing Leads Biolabs Co., Ltd. said its shares will be added to the Hang Seng Composite Index effective March 9, 2026, and will also be included in the Stock Connect Southbound Trading Link eligible list","url":"https://stock-news.laohu8.com/highlight/detail?id=2617468687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617468687?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:11","pubTimestamp":1772788313,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Joins Hang Seng Composite Index Nanjing Leads Biolabs Co., Ltd. said its shares will be added to the Hang Seng Composite Index effective March 9, 2026, and will also be included in the Stock Connect Southbound Trading Link eligible list. Nanjing Leads Biolabs Co., Ltd.  said its shares will be added as a constituent of the Hang Seng Composite Index effective March 9, 2026. The company said the inclusion reflects capital market recognition of its performance and value and is expected to broaden its investor base and improve trading liquidity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL2Gf8sH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178792306","title":"LEADS BIOLABS-B (Stock Code: 09887) Announces First Patient Enrolled in Phase II Trial for Opamtistomig in First-Line Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1178792306","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178792306?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:51","pubTimestamp":1772787065,"startTime":"0","endTime":"0","summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of the announcement referenced here, make no representation as to its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147752592","title":"LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial for VELISIN™ in First-Line Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1147752592","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147752592?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:38","pubTimestamp":1772786322,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating VELISIN™ (PD-L1/4-1BB bispecific antibody, Opatisumimab, LBL-024) for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617684683","title":"Nanjing Leads Biolabs Enrolls First Patient in Phase II ESCC Trial of LBL-024","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684683","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617684683?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:32","pubTimestamp":1772785929,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. said the first patient has been enrolled in an open-label, multi-center Phase II clinical study of Opamtistomig , a PD-L1/4-1BB bispecific antibody, for first-line esophageal squamous cell carcinoma in China. The company said the trial, led by Professor Shen Lin of Beijing Cancer Hospital, will evaluate the efficacy and safety of Opamtistomig in first-line ESCC patients. The company also provided development updates for LBL-024 in extrapulmonary neuroendocrine carcinoma, including National Medical Products Administration approval in April 2024 for a single-arm registrational trial, Breakthrough Therapy Designation from the NMPA in October 2024 for late-line advanced EP-NEC, FDA Orphan Drug Designation for neuroendocrine carcinoma in November 2024, FDA Fast Track Designation for EP-NEC in January 2026, and European Commission Orphan Drug Designation for EP-NEC in January 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL8DBrpD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":139,"code":"91000000","status":"200"}]}}